CeriBell (NASDAQ:CBLL) Given Consensus Recommendation of “Buy” by Analysts

CeriBell (NASDAQ:CBLL) has been given an average rating of “Buy” by the six ratings firms that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $31.20.

Several analysts recently commented on CBLL shares. Bank of America began coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group raised their price target on CeriBell from $30.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. William Blair initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set an “outperform” rating on the stock. Finally, TD Cowen initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $31.00 price target for the company.

CeriBell Price Performance

CBLL stock opened at $28.79 on Friday. CeriBell has a 1 year low of $23.00 and a 1 year high of $29.53.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $17.06 million. Research analysts predict that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.